Sensus Healthcare, Inc.SRTSEarnings & Financial Report
Sensus Healthcare, Inc. is a medical technology company that designs, manufactures and commercializes innovative non-invasive superficial radiation therapy systems. Its products are primarily used for treating non-melanoma skin cancers, keloids, and select cosmetic dermatology conditions, serving healthcare providers and clinical facilities worldwide.
SRTS Q4 FY2025 Key Financial Metrics
Revenue
$4.9M
Gross Profit
$1.9M
Operating Profit
$-3.1M
Net Profit
$-3.2M
Gross Margin
38.4%
Operating Margin
-63.8%
Net Margin
-64.1%
YoY Growth
-62.2%
EPS
$-0.19
Sensus Healthcare, Inc. Q4 FY2025 Financial Summary
Sensus Healthcare, Inc. reported revenue of $4.9M (down 62.2% YoY) for Q4 FY2025, with a net profit of $-3.2M (down 304.9% YoY) (-64.1% margin). Cost of goods sold was $3.0M, operating expenses totaled $5.0M.
Key Financial Metrics
| Total Revenue | $4.9M |
|---|---|
| Net Profit | $-3.2M |
| Gross Margin | 38.4% |
| Operating Margin | -63.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Sensus Healthcare, Inc. Q4 FY2025 revenue of $4.9M breaks down across 2 segments, led by Products at $2.8M (57.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $2.8M | 57.3% |
| Other | $2.1M | 42.7% |
Sensus Healthcare, Inc. Revenue by Segment — Quarterly Trend
Sensus Healthcare, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $2.8M | $4.8M | $5.4M | $6.7M |
| Other | $2.1M | $2.1M | $1.9M | $1.6M |
Sensus Healthcare, Inc. Annual Revenue by Year
Sensus Healthcare, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $27.5M).
Sensus Healthcare, Inc. Quarterly Revenue & Net Profit History
Sensus Healthcare, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $4.9M | -62.2% | $-3.2M | -64.1% |
| Q3 FY2025 | $6.9M | -22.1% | $-943.0K | -13.7% |
| Q2 FY2025 | $7.3M | -20.8% | $-1.0M | -14.2% |
| Q1 FY2025 | $8.3M | -21.7% | $-2.6M | -30.8% |
| Q4 FY2024 | $13.1M | +4.0% | $1.5M | 11.8% |
| Q3 FY2024 | $8.8M | +126.8% | $1.2M | 13.7% |
| Q2 FY2024 | $9.2M | +104.1% | $1.6M | 17.4% |
| Q1 FY2024 | $10.7M | +212.3% | $2.3M | 21.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.7M | $9.2M | $8.8M | $13.1M | $8.3M | $7.3M | $6.9M | $4.9M |
| YoY Growth | 212.3% | 104.1% | 126.8% | 4.0% | -21.7% | -20.8% | -22.1% | -62.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $57.3M | $58.2M | $59.9M | $62.2M | $60.2M | $58.9M | $58.3M | $53.0M |
| Liabilities | $6.1M | $5.3M | $5.7M | $6.3M | $7.2M | $6.8M | $7.1M | $4.9M |
| Equity | $51.2M | $52.9M | $54.1M | $55.8M | $53.0M | $52.1M | $51.2M | $48.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.2M | $4.2M | $4.0M | $-827000 | $-2.7M | $3.1M | $2.3M | $-2.2M |